A Pharmacists Reality Check on the Peptide Headlines
Patients are asking at the pharmacy counter whether they can finally get BPC-157. A June pharmacist breakdown separates what has actually changed in peptide policy from what the headlines suggest.
CagriSema Builds Its Case With New Diabetes Data Before an FDA Decision
Novo Nordisks next big weight-loss hopeful is stacking up evidence. New June diabetes data for CagriSema arrived ahead of an FDA obesity decision expected later in 2026.
Final Days to Comment: The FDAs Compounded-GLP-1 Window Closes June 29
A key public-input window is about to close. Comments on the FDAs proposal to exclude semaglutide, tirzepatide, and liraglutide from bulk compounding are due by June 29, 2026.
How to Vet Your Injector and Your Product in 2026
With new products, pop-up clinics, and online deals everywhere, choosing safely matters more than ever. A practical, neutral checklist for vetting both the person holding the syringe and whats inside it.
FDA Reiterates: Unapproved Injectables Sold Online Are a Real Danger
The warning bears repeating, and the FDA is repeating it. Counterfeit and unapproved toxins and fillers sold online can be contaminated, mis-dosed, or fake, with serious consequences including botulism.
Your Mid-2026 Toxin Map: Whats FDA-Approved and Whats Still Coming
With new names making headlines all year, its easy to lose track of what you can actually get. A mid-2026 snapshot of the FDA-approved toxins available now, and the much-hyped ones still under review.
Less Is More: The 2026 Move Toward Natural, Subtle Results
Overfilled looks are out; undetectable is in. June coverage reinforced a defining shift toward natural, subtle outcomes, enhancing features rather than altering them, and what that means for how patients choose treatment.
From Filling to Rebuilding: The Regenerative Injectable Era Takes Hold
The biggest shift in injectables is no longer about adding volume. June coverage tracked the move toward regenerative options, biostimulators and polynucleotides, that aim to make skin build its own collagen.
Prejuvenation: Why 20- and 30-Somethings Are Starting Early
A growing share of younger patients arent fixing wrinkles, theyre trying to prevent them. June coverage tracked prejuvenation and baby Botox, the micro-dosed, preventative approach reshaping who walks in the door.
After the Weight Loss: Post-GLP-1 Restoration Becomes a Leading Driver
GLP-1 medications change bodies fast, and aesthetics is racing to keep up. June coverage placed post-GLP-1 facial and body restoration among the fastest-growing categories in the field.
Retatrutide Nears the FDA After Posting Nearly 30% Weight Loss
The most potent weight-loss drug in development just moved a step closer. New trial results for retatrutide, a triple-hormone injectable, showed nearly 30% body-weight loss, approaching territory once reserved for surgery.
Non-FDA Medications and the Telehealth Gray Market Draw Scrutiny
Order a peptide or a compounded shot from a slick telehealth site, and the marketing may outrun the law. In 2026, enforcement is sharpening against online platforms making unlawful drug claims.
Approved Abroad Is Not Approved Here: Reading Toxin News Wisely
A flurry of May toxin news, a recombinant approval in China, a liquid toxin cleared in 20-plus markets, can blur an important line. Approved somewhere is not approved here. A consumers guide to telling the difference.
The Comparison the Field Waited For: Dysport vs Botox, Head-to-Head
Two of the most familiar toxins have never been directly compared in a rigorous trial, until now. At a May conference, Ipsen presented the first randomized, double-blind head-to-head of Dysport versus Botox.
Corabotase Posts Its Strongest Data Yet in the Race for a Longer-Lasting Toxin
Patients keep asking why their wrinkle relaxer fades so fast. At a May conference, Ipsens investigational neurotoxin corabotase posted its strongest Phase 2 data yet, aimed squarely at that durability gap.
Two-Year Real-World Data: Tirzepatide vs Semaglutide Weight Trajectories
Trials are one thing; real life is another. A large real-world analysis circulating in May tracked tens of thousands of patients on tirzepatide versus semaglutide over two years, with practical takeaways.
Beyond the Mirror: Aesthetics Starts Measuring Well-Being
How a treatment makes someone feel is becoming part of the data. May research highlighted patient-reported outcomes, including psychological well-being, as a growing way to evaluate aesthetic injectables.
The Rise of Ready-to-Use Liquid Toxins, Explained
Most toxins arrive as a powder a provider must mix before injecting. A May deep dive examined the rise of ready-to-use liquid toxins like Relfydess, which skip that step and aim for more consistent dosing.
A Higher-Dose Wegovy Is Under FDA Review for Stubborn Plateaus
For patients who stall on standard doses, Novo Nordisk wants to go higher. A 7.2 mg dose of injectable semaglutide is under FDA review, aiming to extend results when weight loss plateaus.
Off the Banned List, but Not Approved: Peptides in a Gray Zone
After April removals from the restricted list, where do peptides actually stand? A May pharmacy update gave a clear answer: BPC-157 and others sit in a gray zone, neither prohibited nor clearly permitted.
Microtox Gets a Framework: Hyperdilute Toxin for Skin Quality
Toxin is not just for wrinkles anymore. A May study formalized micro botulinum toxin, injecting hyperdilute toxin into the skin to target pores, texture, and acne, using products providers already know.
AI Enters the Treatment Room: Planning Tools Reach Aesthetics
Artificial intelligence is moving from buzzword to tool in aesthetics. May commentary tracked AI-assisted assessment and treatment planning, with a clear caveat: it supports clinical judgment, it does not replace it.
The Injectables You Should Never Buy Online
Toxins and fillers sold over websites and messaging apps can look like a bargain, and be a serious hazard. With enforcement ongoing in 2026, heres why unauthorized online injectables are a line not to cross.
The Multi-Agonist Race: Inside the Next Generation of Weight-Loss Drugs
One hormone target became two, then three, and the weight-loss pipeline is racing ahead. A neutral map of the multi-agonist contenders, CagriSema, MariTide, survodutide, retatrutide, and what sets them apart.
Better Together: Why Devices Plus Injectables Outperform Either Alone
Injectables soften lines; energy devices tighten and resurface. May evidence reinforced that combining the two, in the right sequence, tends to outperform either approach on its own.
The Underserved Male Patient: A Growing Gap in Aesthetics
Men are spending more per visit than women on aesthetics, yet many practices still treat them as an afterthought. May commentary framed the male patient as both a clinical and a business gap worth closing.
The GLP-1 Patient Is Changing the Aesthetic Consult
More patients walking into aesthetic clinics are on weight-loss medication, and they arrive with more complex structural needs. May commentary argued the consultation itself has to evolve to keep up.
Peptides on the Shelf: A Booming Market With Minimal Oversight
Peptides have leapt from niche biohacking to mainstream e-commerce, sold openly as research chemicals. May analysis put a number on the boom, and a spotlight on the safety gaps it leaves consumers.
The Clock Is Ticking on Compounded GLP-1s: Comment Window Opens
A May 1 Federal Register notice formalized the FDAs move to exclude semaglutide, tirzepatide, and liraglutide from bulk compounding, and opened a public comment window that closes in late June.
The Worlds First Recombinant Botulinum Toxin Wins Approval, in China
Every toxin on the market is grown from live bacteria, until now. Chinas regulator approved Retoxin, the worlds first recombinant botulinum toxin, made by genetic engineering rather than bacterial culture.
FDA Moves to Close the Last Door on Bulk-Compounded GLP-1s
The compounded-GLP-1 era is nearing its end. On April 30, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the remaining pathway for large-scale compounding.
GLP-1s Keep Expanding: New Oral Option, New Conditions Under Study
The newest oral GLP-1 is not just a weight drug in waiting. Like the rest of its class, orforglipron is being studied across a widening set of conditions, part of a 2026 trend pushing GLP-1s well beyond weight and diabetes.
Donor Fat Fillers: Allograft Adipose Volumizers Enter the Conversation
What if you could restore volume without surgery or synthetic filler? Donor-derived allograft adipose products are drawing fresh attention in 2026 as a regenerative volumizer, though they are not a simple swap for fillers.
Peptides Come Off the Restricted List, With Major Caveats
The peptide saga took a concrete step in April: roughly a dozen peptides were moved off the FDAs restricted Category 2 list. But removal is not the same as approval, or even legal compounding, yet.
Exosomes Plus Microneedling Show Early Promise, a Review Finds
One of the buzziest regenerative pairings just got a closer look. An April systematic review found early promise for microneedling combined with exosomes across several skin conditions, while underscoring that the evidence is still emerging.
Your Patient Is on a GLP-1: A Dermatologists Guide to What Comes Next
Weight-loss medicine has become a default part of the aesthetic consult. An April clinician guide laid out how dermatologists are adapting to patients on GLP-1s, and what that means for the people in the chair.
PDRN and Polynucleotide Skin Boosters: The Next Skin-Quality Wave
As the market shifts from volume to skin quality, PDRN and polynucleotide skin boosters are rising fast. A neutral look at what they are, what the interest is about, and where the evidence and approvals stand.
Aprils Injectable-Safety Crackdown: A Landmark Warning Letter and Online Takedowns
Regulators sent a clear April message about where injectables come from. A first-of-its-kind warning letter to a med spa, plus website crackdowns, put the spotlight on supply-chain integrity and counterfeit risk.
A Filler Finally Gets FDA Approval for the Decollete
The chest has long been treated off-label. In April, Merz Aesthetics secured FDA approval of RADIESSE for wrinkles in the decollete, giving a popular but previously unapproved area its first on-label injectable.
New TrenibotE Data: Fast Onset, Short Duration, No Neutralizing Antibodies
April brought fresh Phase 3 data on TrenibotE, the investigational type-E toxin. The standout finding: across repeat treatments, no neutralizing antibodies developed, alongside its signature fast-on, short-off profile.
FDA Approves Foundayo, the Any-Time Oral GLP-1 for Weight Loss
A second oral GLP-1 just arrived, and this one is a true pill in mechanism. On April 1, the FDA approved orforglipron (Foundayo), the first oral, non-peptide GLP-1 for weight loss, taken any time of day with no food or water rules.
From Botox to Bloodwork: Wellness and Longevity Are Reshaping Med Spas
The med spa is no longer just about wrinkles. April commentary tracked a fast blur between aesthetics, wellness, and longevity, as practices add hormones, weight management, and more, with real implications for oversight.
Tirzepatide vs Semaglutide: What a March Review Concludes
Which GLP-1 is better? A March research review comparing tirzepatide and semaglutide lands on a nuanced answer: one tends to win on weight and metabolism, the other has the strongest heart evidence.
Who Is the GLP-1 Aesthetic Patient? New Data on Mindset and Behavior
The weight-loss-drug patient is becoming a defining figure in aesthetic clinics. March data from a major dermatology meeting looked past the face to the mindset, who these patients are and what they want.
Beyond the Cheeks: Fillers for Temple, Chin, and Decolletage Take the Stage
Aesthetics is thinking past the cheeks and lips. March congress data spotlighted hyaluronic acid studies for the temple, chin, and even the decolletage, reflecting a whole-face, whole-area approach to volume and balance.
TrenibotE: The Eight-Hour, Three-Week Toxin Moves Through Late-Stage Data
A toxin that works by tomorrow and fades in a few weeks? March data on TrenibotE, a first-in-class type-E neurotoxin, fleshed out a profile unlike any toxin on the U.S. market, with onset as early as eight hours.
Regeneration and Menopause: Aesthetics Widens Its Lens at AMWC
Aesthetics is looking past wrinkles toward biology. March congress data spotlighted collagen-stimulating biostimulators and a growing focus on menopause-related skin change, reframing injectables as part of long-term skin health.
AMWC Monaco 2026: The Year Big Injectable Science Lands in One Place
The aesthetic world descended on Monaco in late March. At AMWC 2026, the major injectable makers laid out their newest data across toxins, fillers, and regenerative treatments, a useful map of where the field is heading.
APhA 2026: How GLP-1s Are Rewriting Metabolic Medicine
At a major pharmacy meeting in March, experts mapped how fast GLP-1s are evolving, from a new oral pill to next-gen pills awaiting approval, and what that means for the people taking them.
Compounded GLP-1s in March: The Legal and Safety Picture Tightens
The cheap-compounded-GLP-1 era is closing. With shortages resolved and enforcement rising, March was a good moment to understand why compounded semaglutide and tirzepatide are not the same as the approved drugs.